Science and technology

CNL and AECL Continue Pursuit of Closer Ties With Canada’s Academic Community Through MOU With McMaster University

Retrieved on: 
Tuesday, November 29, 2022
Graphite-moderated reactor, Atomic Energy of Canada Limited, Waste management, Environment, McMaster Nuclear Reactor, Laboratory, Organization, Engineering, Isotope, Private sector, Chalk River Laboratories, Vision 2030, Climate change, Environmental science, MOU, Patient, MNR, Government, McMaster, Science and technology, Workforce, National Nuclear Laboratory, Medicine, McMaster University, CANDU, Cancer, Health, Hydrogen, Research, Intellectual property, Neutron, Crown, Radiochemistry, AECL, Safety, CNL, Uranium, Renewable energy, Tourism, Science

CHALK RIVER, Ontario, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology laboratory, is pleased to announce that it has signed a Memorandum of Understanding (MOU) with Atomic Energy of Canada Limited (AECL), Canada’s nuclear Crown Corporation, and McMaster University to pursue collaborative research opportunities. The MOU represents continued progress for Canada’s national nuclear laboratories as it works to build closer ties with Canada’s academic community, and is the third agreement signed in recent weeks with a leading Canadian university that is designed to advance collaborative research in health and environmental sciences, clean energy and nuclear safety.

Key Points: 
  • That is the driving force behind CNLs ongoing outreach and engagement with the academic community, and we are thrilled to further grow our relationship with McMaster University as part of that effort.
  • This agreement is a key step on our path forward, said Amy Gottschling, AECL Vice President, Science, Technology and Commercial Oversight.
  • Together, CNL, AECL and McMaster operate some of the most unique and advanced nuclear facilities and research laboratories, not just in Canada, but around the world.
  • Located in Hamilton, Ontario, McMaster University is among Canadas most research-intensive universities, and the nations preeminent nuclear research institution.

CNL, AECL and Ontario Tech University Partner to Pursue Collaborative Research

Retrieved on: 
Monday, November 28, 2022
Graphite-moderated reactor, Atomic Energy of Canada Limited, Chalk River Laboratories, Waste management, Environment, Computer security, Ontario Tech University, Organization, Isotope, Private sector, Vision 2030, Student, Knowledge, Employment, Partnership, MOU, Government, Science and technology, National Nuclear Laboratory, Nuclear engineering, CANDU, Innovation, Cancer, Health, Hydrogen, Intellectual property, Federation, International Atomic Energy Agency, Crown, AECL, Cooperative, CNL, Uranium, Renewable energy, Medicine, Research, Science

Working in partnership with Ontario Tech University enables us to pool our financial resources, accelerate early-stage research, facilitate the transfer of knowledge, and work together to address the needs of the nuclear industry and the federal government.

Key Points: 
  • Working in partnership with Ontario Tech University enables us to pool our financial resources, accelerate early-stage research, facilitate the transfer of knowledge, and work together to address the needs of the nuclear industry and the federal government.
  • AECL is proud to announce its partnership today with Ontario Tech University, an engaged partner that attracts the best and brightest students and researchers, says Dr. Amy Gottschling, Vice-President, Science, Technology & Commercial Oversight, AECL.
  • As part of our growing nexus, AECL, CNL and Ontario Tech will tackle our nations greatest challenges.
  • Ontario Tech University is excited to enter this dynamic and expanding collaborative phase with both AECL and CNL in strategic areas that include small modular reactors, hydrogen, and integrated energy systems, commented Dr. Les Jacobs, Vice-President of Research and Innovation at Ontario Tech University.

CNL, AECL and the University of Ottawa Sign MOU to Pursue Collaborative Research Opportunities

Retrieved on: 
Thursday, November 24, 2022
University, Graphite-moderated reactor, Heart, Atomic Energy of Canada Limited, Waste management, Environment, Organization, Isotope, Private sector, Chalk River Laboratories, Vision 2030, Partnership, MOU, Government, Radiation, Research, Science and technology, National Nuclear Laboratory, CANDU, Radiobiology, Cancer, Entrepreneurship, Health, Intellectual property, Crown, University of Ottawa, AECL, Safety, CNL, Renewable energy, Uranium, Management, Science

CHALK RIVER, Ontario, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology laboratory, is pleased to announce that it has signed a Memorandum of Understanding (MOU) with Atomic Energy of Canada Limited (AECL), Canada’s nuclear Crown Corporation, and the University of Ottawa to identify and pursue collaborative research opportunities. Building on decades of work together, the MOU formalizes what has been a longstanding relationship between the organizations in order to facilitate joint research projects, foster the professional development of highly qualified personnel, and encourage shared access to specialized infrastructure, all to advance research in health and environmental sciences, clean energy and nuclear safety.

Key Points: 
  • Alongside CNL, AECL is incredibly excited to enter into this agreement with the University of Ottawa, an organization who shares our passion for research, innovation and entrepreneurship, commented Amy Gottschling, Vice-President, Science, Technology & Commercial Oversight, AECL.
  • This objective is at the heart of this agreement with the University of Ottawa, and we are confident that our work will yield results that offer real, meaningful benefits for Canadians.
  • We share their determination to be agile and to seize every opportunity to continually push back the frontiers of research and development.
  • Today it delivers value for Canadians through supporting 14 federal departments and agencies, as well as the global nuclear industry.

Brady Corporation elects Board of Directors and declares regular dividend to shareholders

Retrieved on: 
Wednesday, November 16, 2022
Software, Internet, Electronics, Safety, Brady Corporation, Xerox, Arkema, Common stock, Science and technology, BRC, NYSE, Telecommunication, Global Media & Entertainment, PPG Industries, Brady, Holding company, Management, Science

At the Board of Directors meeting on November 16, 2022, the Board declared a dividend to shareholders of the Company's Class A Common Stock of $0.23 per share, payable on January 31, 2023, to shareholders of record at the close of business on January 10, 2023.

Key Points: 
  • At the Board of Directors meeting on November 16, 2022, the Board declared a dividend to shareholders of the Company's Class A Common Stock of $0.23 per share, payable on January 31, 2023, to shareholders of record at the close of business on January 10, 2023.
  • Brady Corporation is an international manufacturer and marketer of complete solutions that identify and protect people, products and places.
  • Bradys products help customers increase safety, security, productivity and performance and include high-performance labels, signs, safety devices, printing systems and software.
  • Brady is headquartered in Milwaukee, Wisconsin and as of July 31, 2022, employed approximately 5,700 people in its worldwide businesses.

Allurion Announces Appointment of Moderna Co-Founder and MIT Institute Professor Robert S. Langer as Chair of its Scientific Advisory Board

Retrieved on: 
Friday, November 18, 2022
Fitness & Nutrition, Health, Gastric balloon, MIT, Innovation, Iris, National Medal of Science, Therapy, Patient, Multimedia, Weight loss, Science, Obesity, Science and technology, Massachusetts Institute of Technology, United States Air Force Scientific Advisory Board, Chemical engineering, Moderna, History, Food, Management, Pharmaceutical industry

Allurion , a company dedicated to ending obesity, announced today it has appointed Professor Robert S. Langer, Sc.D., as Chairman of its Scientific Advisory Board.

Key Points: 
  • Allurion , a company dedicated to ending obesity, announced today it has appointed Professor Robert S. Langer, Sc.D., as Chairman of its Scientific Advisory Board.
  • View the full release here: https://www.businesswire.com/news/home/20221118005048/en/
    It is an honor to welcome Professor Langer to Allurion, said Dr. Shantanu Gaur, founder and CEO of Allurion.
  • Langer is the co-founder of Moderna Therapeutics and one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT).
  • I am delighted to now lead Allurions Scientific Advisory Board while contributing to the companys mission to end obesity.

Global Synthetic Biology Market to Reach $52.04 Billion by 2028 at a CAGR of 27.89%

Retrieved on: 
Thursday, November 17, 2022
Acid, University of Minnesota College of Food, Agricultural and Natural Resource Sciences, VPS, Synthetic biology, Primary, Xeno, Biology, Biotechnology, Genome, Medicine, DNA synthesis, Biosecurity, Analysis, R, Marketing, Research, MEA, DNA, Risk, USD, Core product, Nanotechnology, Engineering, Enzyme, Genomics, Science and technology, Tool, Fine chemical, Environment, Science, Application, Microfluidics, Health care, Oligonucleotide, Sequencing, Agriculture, Food

The Global Synthetic Biology Market is valued at USD 9.3 Billion in 2021, and it is anticipated to attain a value of USD 52.04 Billion by 2028, at a CAGR of 27.89 % over the forecast period (2022 - 2028).

Key Points: 
  • The Global Synthetic Biology Market is valued at USD 9.3 Billion in 2021, and it is anticipated to attain a value of USD 52.04 Billion by 2028, at a CAGR of 27.89 % over the forecast period (2022 - 2028).
  • The interdisciplinary field of synthetic biology deals with the application of engineering concepts to biology.
  • Synthetic biology has the potential to provide solutions to issues in agriculture, manufacturing, and medicine.
  • The global synthetic biology market is being driven by the application of synthetic biology techniques in medication discovery and development.

Research Study Confirms Efficacy of Doctor's Biome Signature Probiotics Blend

Retrieved on: 
Wednesday, November 16, 2022
Technology, Leadership, Chief technology officer, News, FDA, Patent, CEO, Newgen, GI, Probiotic, LLC, Unit, Clostridium difficile, Science and technology, Dietary supplement

HAUPPAUGE, N.Y., Nov. 16, 2022 /PRNewswire/ -- A new in vitro research study conducted by the Eurofins Labs confirmed efficacy of Doctor's Biome proprietary blend of probiotics (10 lactobacilli and 5 bifidobacteria) in inhibition of Clostridium difficile (C. diff); a life-threatening diarrhea-causing bacteria.

Key Points: 
  • HAUPPAUGE, N.Y., Nov. 16, 2022 /PRNewswire/ -- A new in vitro research study conducted by the Eurofins Labs confirmed efficacy of Doctor's Biome proprietary blend of probiotics (10 lactobacilli and 5 bifidobacteria) in inhibition of Clostridium difficile (C. diff); a life-threatening diarrhea-causing bacteria.
  • "We would like to name this proprietary blend of 15 probiotic bacteria Doctor's Biome Signature Probiotic Blend."
  • Doctors Biome just filed a patent application for its Signature Probiotics Blend.
  • So far, we thought we had a unique technology to offer living probiotics in a blend of organic vegetable-fruit juice but we now know that we also have a signature probiotic blend.

Global Synthetic Biology Market Report 2022: Continued Growth in R&D Investments Fuels Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, November 11, 2022
Biotechnology, Science, Health, Research, Science and technology, Chief executive officer, R, Biology, MEA, Primary, VPS, Tool, Xeno, Enzyme, Analysis, Engineering, Synthetic biology, Medicine, Core product, Research, Solution, Acid, USD, Risk, CAGR, Biosecurity, DNA synthesis, Biotechnology, DNA, Nanotechnology, Genomics, Genome, University of Minnesota College of Food, Agricultural and Natural Resource Sciences, Marketing, Industry, Agriculture, Fine chemical, Sequencing, Health care, Microfluidics, Food, Science, Application, Environment, Technology, Oligonucleotide

The "Global Synthetic Biology Market, By Products, By Application, By Tool, By Technology & By Region- Forecast and Analysis 2022-28" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Synthetic Biology Market, By Products, By Application, By Tool, By Technology & By Region- Forecast and Analysis 2022-28" report has been added to ResearchAndMarkets.com's offering.
  • The interdisciplinary field of synthetic biology deals with the application of engineering concepts to biology.
  • Synthetic biology has the potential to provide solutions to issues in agriculture, manufacturing, and medicine.
  • The global synthetic biology market is being driven by the application of synthetic biology techniques in medication discovery and development.

CNL and General Fusion Sign MOU to Advance Commercial Fusion Energy

Retrieved on: 
Thursday, November 10, 2022
Program, Science and technology, GLOBE, General officer, Health, Atomic Energy of Canada Limited, Economics, AECL, Waste management, Research, Organization, Environment, Plant, Economic development, Technology, UK Atomic Energy Authority Constabulary, Nuclear, CNL, Area studies, General Fusion, National Nuclear Laboratory, Climate change, Deuterium, Electricity, Government, Hydrogen, Vision 2030, Heart, CEO, Private sector, CNRI, Tritium, MOU, Lithium, Renewable energy, Science

Fusion energy holds great potential as a clean and reliable form of energy for electricity grids, and the MOU will act as a framework for both companies to partner to advance fusion energy research and commercialization.

Key Points: 
  • Fusion energy holds great potential as a clean and reliable form of energy for electricity grids, and the MOU will act as a framework for both companies to partner to advance fusion energy research and commercialization.
  • Overall, the aim is to develop fusion energy research capabilities within CNL, to support the goal of constructing a potential General Fusion commercial power plant in Canada before 2030.
  • CNL is thrilled to build on our commercial relationship with General Fusion, a pioneering company that is advancing a new form of clean energy technology, commented Joe McBrearty, CNLs President and CEO.
  • General Fusion is a Canadian company based in Vancouver and we are excited to advance this framework to collaborate with CNL, a leader in clean energy technologies, said Greg Twinney, CEO, General Fusion.

CNL and General Fusion Sign MOU to Advance Commercial Fusion Energy

Retrieved on: 
Thursday, November 10, 2022
Program, Science and technology, GLOBE, General officer, Economics, Research, Organization, Plant, Economic development, Technology, UK Atomic Energy Authority Constabulary, Nuclear, CNL, Area studies, General Fusion, National Nuclear Laboratory, Climate change, Deuterium, Electricity, Hydrogen, Heart, CEO, CNRI, Tritium, MOU, Lithium, Renewable energy, Science

Fusion energy holds great potential as a clean and reliable form of energy for electricity grids, and the MOU will act as a framework for both companies to partner to advance fusion energy research and commercialization.

Key Points: 
  • Fusion energy holds great potential as a clean and reliable form of energy for electricity grids, and the MOU will act as a framework for both companies to partner to advance fusion energy research and commercialization.
  • Overall, the aim is to develop fusion energy research capabilities within CNL, to support the goal of constructing a potential General Fusion commercial power plant in Canada before 2030.
  • CNL is thrilled to build on our commercial relationship with General Fusion, a pioneering company that is advancing a new form of clean energy technology, commented Joe McBrearty, CNLs President and CEO.
  • General Fusion is a Canadian company based in Vancouver and we are excited to advance this framework to collaborate with CNL, a leader in clean energy technologies, said Greg Twinney, CEO, General Fusion.